New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

Andrew C Palfreeman
Kay E McNamee
Fiona E McCann
The Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, London, UK

Abstract: Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis (PsA), a disorder that presents with additional joint inflammation and other clinical features. At present, the most effective treatment for moderate and severe psoriasis and PsA are biologics such as antitumor necrosis factor alpha therapy. Biologics are costly and typically require repeated injections; hence, the development of novel, orally available, small molecular inhibitors that are less expensive to produce is highly desirable. The phosphodiesterase 4 inhibitor apremilast is a small molecular inhibitor that acts by increasing cyclic adenosine monophosphate levels, ultimately suppressing tumor necrosis alpha production. Apremilast has been tested in a number of psoriasis and PsA pilot and Phase II trials to evaluate its efficacy and safety. More recently, three larger double-blinded, and randomized multicenter studies demonstrate that apremilast is efficacious in the treatment of psoriasis and PsA, with significantly higher numbers of apremilast-treated patients achieving endpoints of a 75% reduction compared to baseline in Psoriasis Area and Severity Index (PASI-75) or American College of Rheumatology-20 scores, relative to placebo. This encouraging data, along with a tolerable incidence of mild to moderate adverse events, has led to the initiation of several large Phase III trials that aim to further validate apremilast as a treatment for psoriasis and PsA. Here, we provide an overview of the current treatments for psoriasis and PsA, and summarize the findings from multiple Phase II clinical trials where the effects of apremilast in the treatment of psoriasis and PsA patients have been investigated.

Keywords: apremilast, psoriasis, psoriatic arthritis, phosphodiesterase inhibitor

Introduction

Taking cues from the largely successful treatment of rheumatoid arthritis (RA) with tumor necrosis factor alpha (TNFα) blockade, the treatment of psoriasis and psoriatic arthritis (PsA) has been vastly improved in recent years with the development of biologic therapies that target important inflammatory proteins pivotal for disease progression. Whilst efficacious for a substantial number of patients, a number of drawbacks with this course of therapy prevail. High on the list is the necessary route of administration; biologics must be delivered either intravenously or subcutaneously, mostly requiring regular visits to the clinic for dosing. This inconvenience to the patient, coupled with the relatively high manufacturing costs of biologics, drives continued research and the development of improved, orally available therapies that limit disease progression without impacting on patient lifestyle and well-being. This review provides an overview of the current therapies for
Psoriasis and PsA, and the future prospects for new drugs in the pipeline, with special attention given to apremilast (Celgene Corporation, Summit, NJ, USA), a novel, orally available phosphodiesterase 4 (PDE4) inhibitor, which is now in Phase III clinical trials.

Psoriasis is a chronic immune skin disorder that affects 1%–3% of the world’s population. Often linked with genetic and environmental triggers, it is characterized by hyperproliferation of the skin’s epidermal layer, which is attributed to premature maturation of keratinocytes and dermal inflammatory infiltrates comprising dendritic cells, macrophages and T cells. Affected patients are most commonly found on the scalp, back, and the extensor surfaces (elbows and knees) (Figure 1). While approximately one-third of patients go on to develop PsA, up to 20% of PsA sufferers develop arthritic symptoms prior to plaque formation. PsA presents additionally with joint inflammation and synovitis, but it is distinct from related joint disorders like RA through the inclusion of enthesitis, dactylitis, and spinal involvement (Figure 1), and it is better characterized as a spondyloarthropathy disorder. Psoriasis and PsA patients often have a poor quality of life, and both diseases have a considerable impact on the economy, with the National Psoriasis Foundation (USA) estimating the direct and indirect costs at over US $11 billion annually.

Unsurprisingly, the effective management of psoriasis and PsA is largely dependent on the severity of the disease. Mild psoriatic plaques can be successfully treated topically, with corticosteroids, emollients, coal tar preparations, or vitamin D analogs. For moderate to severe disease, systemic treatments are employed. Initially, patients are often treated with oral therapies such as methotrexate, cyclosporine, and sulfasalazine. Failure to respond to these agents can lead to the patient being placed on a biologic, most commonly an anti-TNFα inhibitor (Table 1). Anti-TNFα biologics have been highly successful in the treatment of psoriasis and PsA, with efficacy measured using the Psoriasis Area and Severity Index (PASI). The PASI assesses psoriatic disease by assigning an ascending score to plaques of increasing severity (thickness, redness, and scaling) and the extent of the plaque spread. Psoriasis patients typically achieve a 75% reduction compared to baseline PASI (PASI-75) in 70%–80% of cases that are treated with either adalimumab or infliximab. Similarly, 59%–68% of PsA patients receiving either agent reach PASI-75. Despite the clear efficacy of anti-TNFα biologics, not all patients respond adequately to treatment. New biologic targets are now being evaluated in the clinic to address this, with a recent focus on targeting Th17 cells (Table 1). Th17 cells are T helper cells defined by their production of interleukin (IL)-17 and require IL-23 for their maintenance. Brodulamab (Amgen Inc, Thousand Oaks, CA, USA), ixekizumab (Eli Lilly and Company, Indianapolis, IN, USA), and secukinumab

Figure 1 Psoriasis and PsA. (A) Psoriasis is associated with a hyperproliferative epidermal layer, abnormal keratinocyte growth, and an inflammatory cell infiltrate including T cells and macrophages. This manifests in inflamed skin and raised plaques with silvery scales and can cover large areas of the body. (B) Glossary of clinical features associated with classification of psoriatic arthritis. Adapted from Bren L. Psoriasis: more than cosmetic. FDA Consumer. 2004 Sept-Oct. Available from: http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2004/504_psoriasis.html. Accessed February 8, 2013.

Abbreviation: PsA, psoriatic arthritis.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Treatment</th>
<th>Mechanism of action</th>
<th>Efficacy</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-TNF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adalimumab</td>
<td>PsA 40 mg SC every other week, psoriasis 80 mg SC at week 0; 40 mg SC every other week thereafter⁵</td>
<td>Fully human monoclonal antibody</td>
<td>PASI-75 achieved in 71% of psoriasis and 59% of PsA patients. PsA ACR20 achieved in 58%⁵</td>
<td>Association with increased prevalence of bacterial, viral, and fungal infections. Reactivation of hepatitis B. Increased tuberculosis recurrence⁴⁶</td>
</tr>
<tr>
<td>Etanercept</td>
<td>PsA 25 mg SC twice a week. Psoriasis 50 mg SC twice weekly for 3 months, 50 mg/week thereafter⁴</td>
<td>Fusion protein to link TNF receptor to the Fc component of human IgG</td>
<td>PASI-75 achieved in 49% of psoriasis and 26% of PsA patients. PsA ACR20 achieved in 59%⁴</td>
<td></td>
</tr>
<tr>
<td>Golimumab</td>
<td>PsA 50 mg SC every month⁷</td>
<td>Human monoclonal antibody (2-week half-life) Phase II trials for psoriasis</td>
<td>PASI-75 achieved in 58% of psoriasis and 58% of PsA patients. PsA ACR20 achieved in 51%⁷</td>
<td></td>
</tr>
<tr>
<td>Infliximab</td>
<td>PsA and psoriasis 5 mg/kg at weeks 0, 2, and 6, and at every 8 weeks thereafter⁶</td>
<td>Chimeric (mouse–human) monoclonal antibody</td>
<td>PASI-75 achieved in 80% of psoriasis and 68% of PsA patients. PsA ACR20 achieved in 58%⁶</td>
<td></td>
</tr>
<tr>
<td>Anti-IL-17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brodalumab</td>
<td>Subcutaneous injection</td>
<td>Anti-IL-17 receptor monoclonal antibody</td>
<td>PASI-75 achieved in up to 82% of PsA patients at 12 weeks (placebo, 0%)¹³</td>
<td>AE reported include nasopharyngitis, injection, nausea, and arthralgia¹³</td>
</tr>
<tr>
<td>Ilekizumab</td>
<td>Subcutaneous injection</td>
<td>Monoclonal anti-IL-17 antibody</td>
<td>Up to 82% PASI-75 improvement at 12 weeks (placebo 7.7%)¹¹</td>
<td>AE include infections, headaches, and nasopharyngitis¹¹</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>Subcutaneous injection</td>
<td>Monoclonal anti-IL-17 antibody</td>
<td>81.5% achieved PASI-75 (150 mg) at 12 weeks (placebo, 9.1%)¹³</td>
<td>AE include pharyngitis, fatigue, and peripheral edema¹³</td>
</tr>
<tr>
<td>Anti-IL-12/IL-23</td>
<td></td>
<td>Human monoclonal antibody anti-p40 subunit</td>
<td>Up to 82% achieved PASI 75 (placebo 6%–7%)³⁰²¹</td>
<td>AE include nasophagytictis headache and infections³⁰²¹</td>
</tr>
<tr>
<td>Briakinumab</td>
<td>Subcutaneous injection</td>
<td>Human monoclonal antibody anti-p40 subunit</td>
<td>Up to 67% achieved PASI-75 (placebo 3.1%)¹⁷</td>
<td>AE include headache, myocardial infarction, and stroke. Potential increase of latent infection¹⁷</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Subcutaneous injection</td>
<td>Human monoclonal antibody anti-p40 subunit</td>
<td>Up to 48% of PsA patients achieved ACR20 in Phase II trial (placebo, 1%)⁷</td>
<td>AE include dizziness, headache, and hypertension. Increased risk of infection³</td>
</tr>
<tr>
<td>Anti-T cell activation</td>
<td></td>
<td>Fully human CTLA-4-IgG1 fusion protein that binds CD80/CD86</td>
<td>Up to 48% of PsA patients achieved ACR20 in Phase II trial (placebo, 1%)⁷</td>
<td>AE include dizziness, headache, and hypertension. Increased risk of infection³</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Subcutaneous injection</td>
<td>Inhibits T cell activation and proliferation</td>
<td>Phase III trial; 33% achieved PASI-75 versus with 13% placebo. PsA (plus MTX) 54% ACR20 versus MTX alone⁶³⁴</td>
<td>No increased incidence for infections⁶</td>
</tr>
<tr>
<td>Alefacept</td>
<td>Intramuscular injection 15 mg once weekly for 12 weeks⁶³⁴</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** PsA, psoriatic arthritis; SC, subcutaneous; PASI, Psoriasis Area and Severity Index; ACR20, American College of Rheumatology-20; TNF, tumor necrosis factor; IgG, immunoglobulin G; IL, interleukin; AE, adverse events; CTLA-4, cytotoxic T-lymphocyte antigen 4; MTX, methotrexate.
(Novartis Corporation, Basel, Switzerland) are antagonistic antibodies that target IL-17. All have demonstrated efficacy in their initial drug trials, and they are currently being studied in Phase III trials for the treatment of psoriasis and PsA.\textsuperscript{11–14} \textbf{Targeting} related pathways, briakinumab (Abbott Laboratories, Abbott Park, IL, USA) and ustekinumab (Janssen Biotech, Inc, Horsham, PA, USA) inhibit the IL-12/IL-23p40 subunit, and have completed Phase III trials for psoriasis and are currently being evaluated in PsA.\textsuperscript{15–19} Notably, results from an additional 12-week trial suggested that psoriasis patients receiving either ustekinumab or briakinumab had a higher clinical response than patients receiving etanercept,\textsuperscript{20–22} suggesting that these emerging biologics may challenge the dominance of anti-TNFα in psoriasis and PsA if their long-term safety profile is acceptable.

A major disadvantage with biologic therapies is that they must be delivered either subcutaneously or intravenously, and they are expensive, with the cost per patient ranging between US $15,000–$30,000+ per year.\textsuperscript{23} Thus, there is a significant need for more cost-effective drugs that can be orally administered that influence proinflammatory cytokines. Small molecular weight inhibitors (SMI compounds with a molecular weight of less than 1 kDa), have been much explored for their potential to treat autoimmune disorders, with manufacturing costs projected to be significantly less expensive than biologics.\textsuperscript{24} The SMI currently being investigated in inflammatory diseases are largely targeted to intracellular signaling pathways, the most explored of which target kinases. Imperative for cellular processes, kinases are attractive targets as they often act upstream of inflammatory mediators such as TNFα, and hence selective blockade can regulate multiple inflammatory processes.\textsuperscript{25} Although many novel kinase inhibitors have been developed in recent times, few have progressed through the clinic. Of these, tofacitinib (Pfizer, Inc, New York, NY, USA) is an oral Janus kinase (JAK) inhibitor that has proven to be efficacious in moderate to severe plaque psoriasis over a 12-week treatment period and is currently in Phase III trials.\textsuperscript{26,27} Tofacitinib is also in Phase Ib trials for PsA after its success in trials with RA patients who had previously failed to respond to biologics;\textsuperscript{28} however, concerns were raised over toxicity when four patients enrolled in the RA Phase III multicenter studies died, where one of these deaths due to respiratory failure was attributed to the drug.\textsuperscript{29} Adding to the concern, a recent study has suggested a link between tofacitinib and reactivation of tuberculosis in a mouse model, further highlighting the need for more thorough investigation into its safety.\textsuperscript{30} Another oral JAK1/2 inhibitor, baricitinib (Eli Lilly and Company; Incyte Corporation, Wilmington, DE, USA), is currently being evaluated in a Phase IIb study for patients with moderate to severe psoriasis, and primary results are expected in 2013.\textsuperscript{31}

**PDE4 inhibition and apremilast**

Although research for oral treatments has been largely dominated by kinase targets, other SMI-targeting alternative pathways are in development, including those designed to inhibit PDE4. Phosphodiesterases comprise a family of enzymes that uniquely hydrolyse and degrade cyclic adenosine monophosphate (cAMP). One of eleven subtypes, PDE4, is widely expressed in numerous cell types, including hematopoietic cells, keratinocytes, endothelial cells, as well as muscle and nerve cells.\textsuperscript{32,33} Amongst its various cellular functions, including roles in apoptosis and lipid metabolism, PDE4 regulates immune and inflammatory processes through control of intracellular cAMP levels and downstream protein kinase A pathways.\textsuperscript{34} In turn, the production of a number of key inflammatory cytokines by myeloid and lymphoid cells is affected, shaping the immune response accordingly.

Specific inhibition of PDE4 in human peripheral monocytes by a number of agents causes decreased production of LPS-induced TNFα.\textsuperscript{35} Monocytes and macrophages chronically treated with ethanol showed increased expression of PDE4B, reduced expression of cAMP, and increased nuclear factor kappa beta (NFκB) signaling, ultimately leading to an increase in lipopolysaccharide-stimulated TNFα production. This effect was abolished by the addition of the classical PDE4 inhibitor, rolipram, highlighting the potential of this class of drug to control NFκB-mediated immune processes.\textsuperscript{36} Intriguingly, such effects are not restricted to the control of proinflammatory mediators. Inhibition of PDE4 has been demonstrated to elevate the anti-inflammatory cytokine IL-10 via protein kinase A-mediated protein interactions with cAMP response elements in the promoter and enhancer regions of the IL-10 gene.\textsuperscript{37,38} Thus, the outcome of limiting PDE4 activity is contextually dependent on effector gene expression and the proximity of NFκB or cAMP response elements in promoter regions. Additionally, PDE4 activity augments effector function in lymphocytes and neutrophils. Inhibition with rolipram suppresses antigen-induced T cell proliferation and cytokine production,\textsuperscript{39} while PDE4 inhibition decreases the production of IL-8, a major chemoattractant for neutrophils. Furthermore, PDE4 increases expression of the B2-integrin Mac-1 on neutrophils, associated with activation and extravasation across endothelial linings.\textsuperscript{33} Thus, the potential of a selective PDE4 inhibitor to control
unwarranted immune responses, pertinent to autoimmunity, is clear. Many of the cytokine mediators of psoriasis and PsA are influenced by PDE4 activity; therefore, specific inhibitors could be beneficial, as previously reviewed. Celgene has developed apremilast (CC-10004; Celgene Corporation), a novel, orally available small molecule that specifically targets PDE4. Effects on lipopolysaccharide-stimulated human peripheral blood mononuclear cells demonstrated the attenuation of a number of cytokines including IFNγ, TNFα, IL-12, and IL-23, and the chemokines CXCL9 and CXCL10. Importantly, this study has also demonstrated the potential of apremilast to restrict TNFα production from keratinocytes and natural killer cells, the major constituent of psoriatic skin lesions.

Recently, in vivo experiments conducted in a classical preclinical model of psoriasis, using normal human skin xenotransplanted onto severe combined immunodeficiency mice, injected with human natural killer cells from psoriatic donors, strongly support a therapeutic role for PDE4 blockade. Orally administered apremilast significantly reduced epidermal thickness and decreased histopathological features of psoriasis plaques. While many mouse models of psoriasis have been described, an equivalent model for PsA combining skin lesions and spondyloarthropathies has not been described. However, the therapeutic effect of apremilast and other PDE4 inhibitors has been tested in human rheumatoid synovial cells and in animal models of arthritis. Inhibitory effects on the spontaneous production of TNFα, IL-1β, and chemokines MCP-1, MIP-1α, MIP-1β, and RANTES from RA synovial cells were observed in the presence of rolflumilast (Takeda Pharmaceutical Company Limited, Osaka, Japan) and two novel PDE4 inhibitors (INH0061 and INH0062; GlaxoSmithKline Inc, London, UK). Similarly, at 0.25 nM to 100 nM concentrations, apremilast dose-dependently inhibited the spontaneous production of TNFα from RA synovial membrane cultures, showing a similar efficacy to the classic PDE4 inhibitor, rolipram.

In classical collagen-induced arthritis in dilute brown non-agouti/1 (DBA/1) mice, clinical and histopathological signs of disease were reduced with daily intraperitoneal injections of 5 mg/kg or 25 mg/kg. Such effects were reproduced in an alternative model of collagen antibody-induced arthritis in BALB/c mice, receiving an oral dose of 25 mg/kg apremilast daily.

**Assessment of apremilast in the clinic**

Having demonstrated the capacity to suppress TNFα in vivo, and indications that it was well tolerated by naïve mice in terms of lethargy relative to those dosed with rolipram, apremilast held significant promise when entering Phase II clinical trials. Since the early development of PDE4 inhibitors, one of the main concerns has been the associated adverse events (AE). These side effects tend to primarily affect the gastrointestinal system, resulting in nausea and emesis, as well headaches. It has been shown that these AE are a result of the inhibition of the PDE4D isoform. Interestingly, apremilast does not selectively inhibit any specific isoform of PDE4, but it does appear to be void of these typical complications, and the majority of reported AE are classed as “mild to moderate” by investigators.

The total number of clinical trials involving apremilast currently stands at 39. These include small Phase I trials and pilot studies investigating efficacy in a number of conditions including atopic dermatitis, erythematotelangiectatic rosacea, acne, acute gout, uveitis, vulvodynia, and prurigo nodularis. Nine studies have published their results and are summarized in Table 2. There are a total of four published trials assessing the efficacy of apremilast in psoriasis or PsA, which we will look at in this review. Amongst the completed Phase II trials, three stand out due to the substantially higher number of enrolled participants, exceeding 200 in each study. These trials were well conducted and contained patients displaying similar demographic and baseline characteristics between the randomized groups. Strikingly, all three have yielded positive results when testing apremilast against placebo, as well as displaying a dose-dependent effectiveness in both psoriasis and PsA. The first trial of apremilast in the treatment of psoriasis was published in 2008. Eight out of the 19 patients receiving apremilast achieved the primary endpoint of a reduction in epidermal thickness of ≥20% (classified as responders), with one other patient reaching a 19.9% reduction. Four other patients experienced reductions of <20%. Accompanying the positive clinical response, a decreased number of T cells and CD11c-expressing cells in the dermis and epidermis was observed in responders, thus illustrating apremilast’s potential biological activity. In this study, 14 of the 19 patients (73.7%) saw an improvement in their disease state according to their PASI score. At least one AE (the most common being nausea and headaches) was observed in 14 patients (73.7%), but most of these were classified as mild by the investigators. While this study involved only a small number of patients, it demonstrates the ability of apremilast to successfully and safely treat psoriasis in some patients.

The two largest Phase II trials investigating the effectiveness of apremilast in psoriasis treatment were led by Dr Kim Papp et al. Each trial has been double-blinded and involved a robust number of participants, 259 and 352 respec-
<table>
<thead>
<tr>
<th>Lead author</th>
<th>Date</th>
<th>Disease</th>
<th>Type</th>
<th>Treatments</th>
<th>Number enrolled</th>
<th>Outcome</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papp et al</td>
<td>June 2012</td>
<td>Psoriasis</td>
<td>Phase IIb</td>
<td>10 mg, 20 mg, 30 mg BID, and placebo.</td>
<td>352</td>
<td>Subjects treated with apremilast at 10 mg, 20 mg, and 30 mg BID reached PASI-75 at the respective rates: 11%, 29%, and 41%. This was compared to 6% of the placebo group.</td>
<td>No serious AE seen. Headaches and nausea reported.</td>
</tr>
<tr>
<td>Papp et al</td>
<td>August 2012</td>
<td>Psoriasis</td>
<td>Phase II</td>
<td>20 mg SID, 20 mg BID, and placebo.</td>
<td>259</td>
<td>24.4% of subjects treated with 20 mg BID of apremilast reached PASI-75. Both the 20 mg SID and placebo groups saw 10.3% of patients reach PASI-75.</td>
<td>Few more AE compared to apremilast, but most considered mild and tolerable.</td>
</tr>
<tr>
<td>Schett et al</td>
<td>October 2012</td>
<td>Psoriatic arthritis</td>
<td>Phase II</td>
<td>20 mg BID, 40 mg SID, and placebo.</td>
<td>204</td>
<td>Apremilast was more successful at achieving ACR20, 20 mg BID (43.5%), 40 mg SID (35.8%), compared to placebo (11.8%). Rerandomizing the placebo group after the 12-week period also proved that apremilast was effective.</td>
<td>Slightly higher incidence of AE with apremilast compared to placebo, but not significant.</td>
</tr>
<tr>
<td>Samrao et al</td>
<td>August 2012</td>
<td>Atopic dermatitis</td>
<td>Pilot study</td>
<td>20 mg, 30 mg BID, and no placebo or control.</td>
<td>83</td>
<td>Small dose-dependent effect observed with apremilast. Results were moderate, but did show statistical significance.</td>
<td>No serious AE seen. Headaches and nausea reported.</td>
</tr>
<tr>
<td>Pathan et al</td>
<td>September 2012</td>
<td>AS</td>
<td>Phase II</td>
<td>30 mg BID and placebo.</td>
<td>38</td>
<td>The primary endpoint was not met, but six patients treated with apremilast met ASA20, compared to three on placebo. Significant reduction in serum RANKL was observed by apremilast treatment. Epidermal thickness was reduced by a mean of 20.5 mm, and PASI score improved in 73.7% of patients. Apremilast reduced the number of T cells and CD11c cells.</td>
<td>Similar AE observed between apremilast and placebo. Higher rate of headaches and loose stools in the apremilast group. Two patients withdrew from the apremilast group due to severe AE. 73.7% patients experienced at least one AE. Headsaches and nausea reported.</td>
</tr>
<tr>
<td>Gottlieb et al</td>
<td>May 2008</td>
<td>Psoriasis</td>
<td>Phase II</td>
<td>20 mg SID and no placebo or control.</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paul et al</td>
<td>August 2012</td>
<td>Lichen planus</td>
<td>Pilot study</td>
<td>20 mg BID and no placebo or control.</td>
<td>10</td>
<td>Three out of ten patients achieved a two-grade improvement in PGA. All patients demonstrated statistically significant clinical improvement.</td>
<td>No serious AE seen. Headaches and nausea reported.</td>
</tr>
<tr>
<td>Voil et al</td>
<td>March 2012</td>
<td>Recalcitrant allergic contact or atopic dermatitis</td>
<td>Phase II</td>
<td>20 mg BID and no placebo or control.</td>
<td>10</td>
<td>Two patients displayed ≥ 2 improvement of Investigator Global Assessment at week 12. Secondary endpoints of EASI-75 and EASI-50 were met by 10% and 20% of patients, respectively.</td>
<td>No serious AE seen. Headaches and nausea reported.</td>
</tr>
<tr>
<td>De Souza et al</td>
<td>October 2012</td>
<td>Discoid lupus erythematosus</td>
<td>Phase II</td>
<td>20 mg BID and no placebo or control.</td>
<td>8</td>
<td>Significant decrease in CLASI score after 85 days observed in patients.</td>
<td>No serious AE seen. Headaches and nausea reported.</td>
</tr>
</tbody>
</table>

**Abbreviations:** BID, twice a day; PASI, Psoriasis Area and Severity Index; AE, adverse events; SID, once a day; ACR20, American College of Rheumatology; AS, ankylosing spondylitis; RANKL, receptor activator of nuclear factor kappa-B ligand; EASI, Eczema Area Severity Index; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index.
tively, across multiple sites. The first study was conducted between April 2006 and May 2007 across 30 sites in Canada, as well as in the Czech Republic and Germany. The investigators compared apremilast at doses of 20 mg once daily (SID), 20 mg twice daily (BID), and a placebo. Employing the endpoint of PASI-75, only the higher dose (20 mg BID) was significantly more effective than placebo, with efficacy observed in 21 out of 86 patients (24.4%), compared to nine out of 87 patients (10.3%) for both the apremilast 20 mg SID and placebo group. When applying a PASI-50 endpoint, the results of the apremilast 20 mg BID group improved to 49 out of 86 patients (57.0%), and the apremilast 20 mg SID group to 24 out of 87 patients (27.6%) meeting the target, suggestive of a dose-dependent response. Both treatment regimens provided enhanced efficacy over the placebo where 20 mg of 87 patients (23.0%) reached PASI-50. No serious AE were seen, and both doses of apremilast were well tolerated. The most common AE recorded were headaches, nasopharyngitis, diarrhea, and nausea. This study clearly demonstrated that apremilast is effective at treating moderate to severe psoriasis. Given that no serious AE were seen with a dose of 20 mg BID, and considering the dose-dependent results that were indicated, Papp et al suggested a higher dose could be used in future trials.

Following on, the second of Papp et al’s clinical trials, which was also conducted across multiple sites in the USA and Canada, investigated a dosing regimen of 10 mg, 20 mg, and 30 mg BID versus placebo in a total of 352 patients suffering from moderate to severe psoriasis. Again, the primary endpoint was PASI-75, but this time the study was extended from 12 to 16 weeks. A total of 6% of the placebo group reached PASI-75 compared to 11%, 29%, and 41% of the 10 mg, 20 mg, and 30 mg groups, respectively. The two highest doses were significantly efficacious when compared to placebo, unequivocally illustrating the dose-dependent characteristics of apremilast as suggested in the first of Papp’s clinical trials. An additional dimension to this trial involved the placebo group being placed on either 20 mg or 30 mg BID of apremilast at week 16 for a further 8 weeks. The improvement in PASI score in these patients was rapid and by week 24 the mean change from baseline was on par with patients that had started treatment with 20 mg or 30 mg BID of apremilast at week 0. Apremilast was effective in reducing disease severity in a number of other measurements, including Dermatology Life Quality Index scores and the Short Form-36 mental component summary scores. During the first 16-week period of the trial, 255 out of 352 patients (72.4%) suffered at least one AE, and during the period of weeks 16–24 the ratio changed to 121 out of 280 (43.2%). Of these, most were considered to be mild to moderate.

Another encouraging Phase II clinical trial investigating the effect of apremilast in the treatment of PsA was led by Professor Georg Schett in Germany. In this trial, 204 patients received either 20 mg BID, 40 mg SID, or placebo. The primary endpoint was the achievement of a 20% reduction in disease according to the American College of Rheumatology criteria (ACR20). In all, 165 patients completed the treatment phase (12 weeks) and 11.8% of the placebo group reached ACR20, compared to 43.5% of the 20 mg BID group and 35.8% of the 40 mg SID group. Further to this, patients that were receiving placebo were then rerandomized at week 12 to receive either 20 mg BID or 40 mg SID of apremilast for another 12 weeks. By week 24 in both apremilast groups > 40% had achieved ACR20. While this data is positive, more trials in PsA are required to assess the limitations of apremilast. When evaluating ACR20, the ratio of success was 11.8%:43.5%:35.8% (placebo:apremilast 20 mg BID: apremilast 40 mg SID) after the treatment phase. Although it is difficult to conclude until a direct comparison is conducted, the success rate of apremilast in this study is less than that observed for anti-TNFα treatment of PsA (51%–59% meet ACR20; see Table 1), thus highlighting that more needs to be done to establish whether apremilast confers overall benefits compared to currently available biologics.

To date, there are nine Phase III clinical trials underway at several sites, which are due for completion from 2014 onwards (listed in Table 3); the majority of these trials are assessing the effects of multiple doses of apremilast in treating patients with PsA, psoriasis, ankylosing spondylitis (AS), sarcoidosis, and cutaneous sarcoidosis (summarized in Table 3).

While this review is focusing on the treatment of psoriasis and PsA, the documented effects of apremilast in the treatment of related autoimmune diseases such as RA and AS are noteworthy. Although three Phase II trials have been registered to assess the safety and effectiveness of apremilast in RA patients, none have so far yielded results. Two trials that were initiated in 2010 (NCT01285310 and NCT01204138) have not yet published the results. Recruitment is ongoing for a third Phase II trial (NCT01250548), and therefore it remains too early to ascertain the efficacy of apremilast in RA. Perhaps more akin to PsA is the related spondyloarthritis, AS. Genetic studies have revealed an association between psoriasis and AS with common susceptibility genes IL-23R, IL-12B, STAT3, and CARD9. Due to the similarities in genetics and clinical manifestations, it was
Data from three large-scale, multicenter Phase II clinical trials report apremilast to be both efficacious and well tolerated in the treatment of psoriasis and PsA. It has proven successful in achieving PASI-75 in some patients (the most widely used clinical assessment for psoriasis) in these studies, and has been consistently more efficacious than placebo in each case. However, the percentages of patients reaching PASI-75 or ACR20, even at higher doses of apremilast, are not on par with those treated with biologics. Apremilast treatment sees a maximum of 41% of patients reaching PASI-75 or ACR20, even at higher doses. While many patients treated with apremilast still suffer AE, they tend to be mild in severity. The ongoing Phase III trials will go some way to thoroughly determine whether efficacy outweighs the AE profile, to qualify apremilast to be the first PDE4 inhibitor licensed for treatment of psoriasis and PsA. At present, the data available indicates that apremilast is not as effective as the biological therapies currently in use. However, the only fair test is a side-by-side comparison, such as the phase III trial currently underway in North America, Belgium, and Netherlands (NCT01690299), which is directly comparing the effects of apremilast with etanercept for treatment of psoriasis. It is the only Phase III trial that included a biologic as a comparator, as opposed to just a placebo. In addition to efficacy, this head-to-head comparison will be crucially informative on the relative intensity of AE and tolerability. At present, biologics are the leading treatment for moderate to severe psoriasis and PsA. Provided that AE remain mild and well tolerated, and given the lower costs and oral availability, the further clinical development of apremilast seems assured if efficacy proves to be on par with TNF inhibitors. That has yet to be proven, and until the ongoing Phase III trials can be evaluated, the future of apremilast for the treatment of psoriasis and PsA is uncertain.

**Table 3** Summary of registered Phase III clinical trials investigating the effectiveness of apremilast to treat psoriasis, psoriatic arthritis, ankylosing spondylitis, and sarcoidosis

<table>
<thead>
<tr>
<th>Trial name</th>
<th>NCT number</th>
<th>Disease</th>
<th>Treatments</th>
<th>Number enrolled</th>
<th>Completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PALACE-1</td>
<td>NCT01172938</td>
<td>Psoriatic arthritis</td>
<td>20 mg, 30 mg, placebo + 20 mg, placebo + 30 mg (all BID)</td>
<td>495</td>
<td>September 2015</td>
</tr>
<tr>
<td>PALACE-2</td>
<td>NCT01212757</td>
<td>Psoriatic arthritis</td>
<td>20 mg, 30 mg, placebo + 20 mg, placebo + 30 mg (all BID)</td>
<td>495</td>
<td>November 2015</td>
</tr>
<tr>
<td>PALACE-3</td>
<td>NCT01212770</td>
<td>Psoriatic arthritis</td>
<td>20 mg, 30 mg, placebo + 20 mg, placebo + 30 mg (all BID)</td>
<td>495</td>
<td>November 2015</td>
</tr>
<tr>
<td>PALACE-4</td>
<td>NCT01307423</td>
<td>Psoriatic arthritis</td>
<td>20 mg, 30 mg, placebo + 20 mg, placebo + 30 mg (all BID)</td>
<td>495</td>
<td>March 2014</td>
</tr>
<tr>
<td>ESTEEM 1</td>
<td>NCT01194219</td>
<td>Plaque psoriasis</td>
<td>30 mg BID and placebo</td>
<td>844</td>
<td>November 2016</td>
</tr>
<tr>
<td>ESTEEM 2</td>
<td>NCT01232283</td>
<td>Plaque psoriasis</td>
<td>30 mg BID and placebo</td>
<td>413</td>
<td>December 2016</td>
</tr>
<tr>
<td>POSTURE</td>
<td>NCT01583374</td>
<td>Ankylosing spondylitis</td>
<td>20 mg, 30 mg, placebo (all BID)</td>
<td>456</td>
<td>December 2018</td>
</tr>
<tr>
<td>POSTURE</td>
<td>NCT00794274</td>
<td>Sarcoidosis; cutaneous sarcoidosis</td>
<td>20 mg BID, no placebo</td>
<td>20</td>
<td>December 2011</td>
</tr>
</tbody>
</table>

**Abbreviations:** NCT, National Clinical Trial; PALACE, Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis; BID, twice a day; ESTEEM, Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients with Moderate to Severe Plaque Psoriasis; POSTURE, Study of Apremilast to Treat Subjects with Active Ankylosing Spondylitis.
Disclosure

The authors report no conflicts of interest in this work.

References


